Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $74M (up 88.0% year over year) with net income of −$18M.
Q2 2026 key financials · XBRL
- Revenue
- $74M
- +88.0% YoY · +27.4% QoQ
- Net income
- −$18M
- +76.8% YoY · +42.1% QoQ
- Operating margin
- -5.3%
- Gross margin
- 79.7%
- EPS (diluted)
- −$0.21
- +80.0% YoY · +43.2% QoQ
Source: XBRL data from the Phathom Pharmaceuticals, Inc. (PHAT) Q2 2026 10-Q on SEC EDGAR. USD.
Phathom Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $74.3M vs $39.5M, up $34.8M YoY from VOQUEZNA products
- Gross margin 79.7% vs 87.2% YoY, reflecting higher royalties and fulfillment costs
- Operating loss $4.0M vs $59.9M YoY, with SG&A down $30.0M
- Cash $182.5M at June 30, 2026, with $175M Hercules refinancing and maturity extended to February 2029
- Topline Phase 2 EoE results expected Q4 2026; management expects lower near-term net losses
Risk Factors
- No material changes to risk factors disclosed in the 2025 Form 10-K
- No newly added risk factor or quarter-specific trigger disclosed
- Regulatory and compliance risks carried forward from the 2025 Form 10-K
- Operational, competitive, and market risks unchanged from the 2025 Form 10-K
- Liquidity, debt maturity, currency, and concentration risks unchanged from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Phathom Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.